Cardiologists recognize elevated lipoprotein(a) as a distinct genetic driver of cardiovascular morbidity. However, acute coronary events provoke intense systemic inflammation that can alter circulating biomarker levels. Consequently, clinicians often debate the reliability of assessing lipoprotein(a) after myocardial infarction during the index hospital admission. Recent findings from the FRENCHIE-Lp(a) prospective cohort shed crucial light on temporal variability and offer pragmatic screening strategies.

Understanding Lipoprotein(a) After Myocardial Infarction

Atherosclerotic cardiovascular disease remains a leading cause of premature mortality worldwide. While low-density lipoprotein cholesterol receives widespread clinical attention, elevated lipoprotein(a) confers independent, lifelong cardiovascular risk. Lipoprotein(a) consists of an LDL-like particle covalently bound to apolipoprotein(a). This structure promotes both atherogenesis and thrombosis. Because circulating concentrations depend almost entirely on genetic inheritance, guidelines historically suggested checking levels only once in a lifetime.

Nevertheless, acute tissue injury complicates lipid assessment. Myocardial infarction triggers acute-phase reactants, cytokine release, and temporary hepatic metabolic changes. Therefore, early measurements may deviate from an individual's true baseline state. Many clinicians postpone lipid testing until several weeks post-discharge to avoid spurious values. However, delaying assessment frequently causes lost follow-up opportunities in high-risk patients. When clinicians discharge patients without a definitive screening plan, preventive measures remain delayed. In addition, emerging clinical trials mandate strict cutoff thresholds to select eligible candidates for novel therapies. Understanding how concentrations fluctuate between admission, discharge, and convalescence is therefore vital. Clinicians require clear guidance on interpreting acute values accurately.

Design and Methodology of the FRENCHIE-Lp(a) Cohort

To evaluate acute variations objectively, the French Alliance for Cardiovascular Clinical Trials established the FRENCHIE-Lp(a) substudy. This multicenter study prospectively enrolled consecutive adult patients admitted for acute myocardial infarction across 21 tertiary hospitals. The study protocol captured both ST-elevation and non-ST-elevation myocardial infarction presentations to reflect daily hospital practice.

Investigators measured lipoprotein(a) mass concentrations at three distinct clinical timepoints. First, nursing staff drew baseline samples immediately upon hospital admission. Second, teams collected subsequent samples at hospital discharge, representing the subacute phase of recovery. Finally, researchers obtained convalescent samples between three and twelve months during stable outpatient visits. The protocol analyzed concentrations both continuously and across standard categorical intervals: 20 mg/dL or less, 21 to 50 mg/dL, 51 to 70 mg/dL, and greater than 70 mg/dL. The authors defined stable follow-up values as the true clinical reference standard. Subsequently, they conducted cumulative threshold analyses. This statistical model sought to identify acute cut-offs that minimize patient misclassification. Specifically, researchers evaluated which acute threshold accurately predicted follow-up levels exceeding 70 mg/dL.

Temporal Variability Across Admission, Discharge, and Follow-Up

The analysis revealed essential nuances regarding biological fluctuations during acute coronary syndromes. In many individuals, lipoprotein(a) levels remained relatively stable across the initial presentation and subsequent hospital discharge. However, a significant subset of patients exhibited notable shifts. Systemic inflammation, marked by elevated C-reactive protein, correlated with temporary changes in plasma protein synthesis.

Furthermore, concentrations measured at hospital discharge occasionally demonstrated greater deviation from baseline than admission values. As myocardial tissue heals, inflammatory signals peak within several days after coronary artery occlusion. Consequently, discharge samples often captured transient surges or declines induced by systemic stress and medical stabilization. Nevertheless, categorical rank preservation remained high for patients at the extreme ends of the distribution. Patients with extremely low levels upon admission rarely crossed into high-risk categories during follow-up. Similarly, patients with markedly elevated initial values almost universally maintained elevated concentrations months later. The greatest classification uncertainty appeared among individuals with intermediate values between 50 and 70 mg/dL. For this borderline subgroup, acute concentrations alone proved insufficient to guarantee accurate long-term categorization.

Establishing Pragmatic Thresholds for Clinical Trial Eligibility

Modern cardiovascular drug development prioritizes therapies targeting apolipoprotein(a) synthesis. Several landmark phase III randomized clinical trials utilize a threshold of 70 mg/dL, or roughly 150 nmol/L, to select participants. Therefore, identifying patients who truly meet this threshold during acute hospitalization carries profound therapeutic implications.

To solve this dilemma, researchers established pragmatic screening boundaries. They sought an admission threshold below which virtually no patient would exceed 70 mg/dL during outpatient recovery. When admission levels fell well below intermediate boundaries, the risk of late misclassification dropped to negligible levels. Hence, clinicians can confidently exclude patients with very low acute concentrations from requiring prompt follow-up retesting. Conversely, patients presenting with admission values comfortably above 70 mg/dL nearly always remain eligible for targeted therapies. The investigators demonstrated that an admission measurement acts as an effective triage filter. Thus, hospital teams can identify candidates for clinical trials or aggressive risk reduction before hospital discharge. In contrast, patients with borderline values require mandatory outpatient confirmation after acute inflammation subsides. This structured approach optimizes healthcare resources and prevents premature exclusion of eligible patients.

Clinical Implications for Secondary Prevention in Indian Practice

Cardiovascular disease manifests aggressively and at a much younger age in Indian populations. Epidemiological surveys confirm that South Asians exhibit higher median lipoprotein(a) concentrations than European cohorts. Consequently, premature acute myocardial infarction frequently strikes individuals in their thirties and forties across India. Despite intensive statin regimens and optimal low-density lipoprotein control, residual atherothrombotic risk remains substantial.

Therefore, acute admission presents a critical, captive window for Indian physicians to initiate comprehensive risk stratification. Waiting for routine outpatient follow-up often fails in real-world Indian settings due to high loss-to-follow-up rates. By implementing the FRENCHIE-Lp(a) screening algorithm, hospital teams can identify high-risk individuals immediately upon admission. Clinicians can confidently categorize patients with markedly elevated admission values as candidates for intensive secondary prevention. Furthermore, treating teams can educate families regarding cascade testing while the patient remains hospitalized. For patients showing borderline levels, discharge summaries must explicitly mandate repeat outpatient testing three months later. In this manner, Indian cardiologists can maximize preventive interventions, enroll patients into clinical registries, and mitigate long-term recurrent ischemic risk.

Can clinicians reliably measure lipoprotein(a) during acute myocardial infarction?

Yes, clinicians can reliably measure lipoprotein(a) upon hospital admission to screen patients. Although acute systemic inflammation can alter circulating levels, extreme concentrations remain highly consistent over time. Patients presenting with very low or very high values rarely change categories during outpatient convalescence. However, clinicians should recheck intermediate values between 50 and 70 mg/dL during stable follow-up, because acute physiological stress may transiently obscure the true baseline in this specific borderline group.

Why is the 70 mg/dL cutoff significant in clinical practice?

The 70 mg/dL threshold, equivalent to approximately 150 nmol/L, identifies patients at markedly elevated cardiovascular risk who experience significant atherothrombotic events. Furthermore, major phase III clinical trials investigating emerging RNA-targeted therapies, such as pelacarsen and olpasiran, utilize this specific cutoff as their primary enrollment criterion. Establishing whether an acute measurement reliably predicts stable values above 70 mg/dL allows cardiology teams to identify eligible candidates before hospital discharge without losing patients to follow-up.

Why should Indian cardiologists prioritize early lipoprotein(a) assessment?

South Asian individuals have a heightened genetic predisposition to elevated lipoprotein(a), predisposing them to premature, multi-vessel coronary artery disease. In India, acute myocardial infarction frequently presents at young ages, often in patients lacking conventional risk factors. Inpatient testing guarantees risk identification before discharge, bypassing widespread outpatient attrition. Early detection enables clinicians to intensify baseline secondary prevention, implement aggressive lifestyle interventions, and initiate cascade family screening across high-risk relatives who share similar genetic vulnerabilities.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Simon T et al. Variability of lipoprotein(a) levels in patients with acute myocardial infarction between admission, discharge, and follow-up. Eur J Prev Cardiol. 2026 Nov 08. doi: undefined. PMID: 42999996.
2. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerosis and cardiovascular disease: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946.
3. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-392.